2015-347 – Mayo Clinic has developed compositions and methods for detecting soluble PD-L1
2013-237 – Bim is a biomarker for PD-1 and PD-L1 therapies.
2002-064 – Mayo Clinic has patent rights broadly claiming the use of PD-L1 antibodies to treat cancer.
1998-039 – Through the use of gene targeting in mouse embryonic stem (ES) cells we have successfully generated a line of mice deficient in eosinophil granule major basic protein-1 (mMBP-1). These mice would be useful in drug discovery programs directed toward developing treatments for asthma, allergy, inflammation and a variety of eosinophil-related disorders. PMID: 11067904
2010-196 – iPhil mouse line permitting inducible loss of eosinophils to study eosinophil-related diseases. Genotype/Phenotype: Inducible ablation of eosinophils is accomplished through expression of the human diptheria toxin receptor exclusively in cells of the eosinophil lineage. Diptheria toxin exposure completely eliminates circulating osinophils without affecting other cell types. Depletion is... Read More
2000-124 – Rat IgG Monoclonal Antibody Reactive Against Murine MBP Major basic protein, Clone 14.7.4 Known Applications: Immunohistochemistry (IHC), Western blot (WB) Known Reactivity: Mouse NIH publication 11067904
2013-082 – Antigen specific recognition is involved in adaptive immune responses. Most T lymphocytes express an antigen specific αβ T Cell Receptor (TCR) responsible for recognizing its ligand (peptide/MHC) and responding through various effector functions. In an attempt to better understand TCR function, extensive efforts have been placed in discerning the structural and biochemical makeup of the TCR.... Read More
2011-250 – The immune function plays an important role in many diseases including cancer. However, it is often difficult to interpret the role and responsibility of immune cells during treatment because it has been difficult to visualize all components of the immune response. We have taken global approach to understanding the immune system by measuring common multi-factorial immune profiles in patients... Read More
2011-092 – T cells drive adaptive immune responses that can turn out pathogenic when directed against your own body tissues and organs causing autoimmune diseases. On the other hand, T cells are the main cellular component driving acute organ rejection after transplantation. Therefore different strategies to deplete/inactivate T cells have been pursued to treat patients either suffering from autoimmime... Read More
Establishment and Characterization of an Immunoglobulin Lambda Secreting Cell Line from a Patient with AL Amyloidosis
2007-050 – The ALMC-1 and ALMC-2 cell lines were established from samples before and after peripheral blood stem cell transplant. Both cell lines secrete lambda light chains and these light chains have been shown to contain a beta structure, which is necessary for the configuration of amyloid. Therefore, this cell line provides a useful tool to study the underlying biology of amloidogenic light chains... Read More
2005-316 – These mice do not express the gene for CD229.
2003-196 – Transgenic mice were created through DNA microinjection of a construct utilizing mouse EPO derived regulatory sequences in conjunction with the Diptheria Toxin A chain (DT-A) open reading frame and a series of exons/introns derived from the human growth hormone gene to provide the necessary splicing events required for high-level expression. Assessments of circulating leukocytes and other... Read More
2002-039 – Technology Description T cell-mediated immune responses are often harmful in transplant patients and patients with autoimmune disease. Currents treatments to suppress T cell-mediated immune responses include a number of immunosuppressive and anti-inflammatory therapies. A novel means of suppressing this immune response has been developed that utilizes mutant forms of a protein normally... Read More
2000-065 – Mouse class II-deficient HLA-DQB10302, DQA10301 (DQ8) transgenic mice are susceptible to severe collagen-induced arthritis (CIA), an animal model for rheumatoid arthritis. To examine whether polymorphism at the DRB1 locus can modulate DQ-restricted arthritis, we generated double- transgenic (DR/DQ) mice. DRB1*0301 (DR3) was introduced into CIA susceptible DQ8.Abeta transgenic mice to generate... Read More
2000-064 – We developed an HLA-DR3.Abo mouse by introducing the DR3 transgene into a H2Abo mouse, class II negative strain, by mating with BIO.M-DRB1*0301 mice. Experimental autoimmune thyroiditis (EAT) is induced in these mice when immunized with either MTg or HTg.
1999-065 – Investigators are combining mEPO and together with mEPO deficient gene knock-out animals to create a battery of monoclonal antibodies against this eosinophil granular ribonuclease. Highly specific, sensitive antibodies will be produced that will be useful in assays and drug discovery programs for eosinophil-related diseases such as asthma, allergy and inflammation.
1999-064 – Investigators have developed a rabbit polyclonal antisera reactive against murine major basic protein-1 (native protein purified from isolated mouse eosinophils). MBP is a known factor in the asthma, inflammation and allergy pathways. This antibody is highly specific and would be useful in a variety of assays where high specificity and sensitivity are desired.
1997-071 – We generated an HLA-DR4ß(NT) transgene construct in which positions 110 and 139 were altered to resemble endogenous mouse H2 Aß molecules. This construct was introduced into (B10 x SWR) embryos, and DR4ß(NT) transgenic mice were produced. The transgene was transferred into B10.RFB3 (Eß0 Ealphap) mice. The transgene-encoded DR4ß molecules paired with endogenous Ealpha chains to form stable... Read More
1995-140 – Transgenic mouse models for asthma were developed that express interleukin-5 under the control of a lung epithelial specific promoter. All mice express abnormally high levels of eosinophils in those regions and display symptoms consistent with the underlying physiologic conditions. The CCIL-5 mouse line is a superb animal model for the study of asthma. The animals show hyperactivity to... Read More
1995-139 – Transgenic mouse models for eosinophil-mediated tissue inflammation were developed that express interleukin-5 under the control of a T-cell specific promoter. All mice express abnormally high levels of eosinophils in those regions and display symptoms consistent with the underlying physiologic conditions. The NJ1638 mice are models for hypereosinophilic syndromes and have high levels of... Read More
1988-049 – HMC-1 is a one-of-a kind human cell line which can serve as a resource for mast cell proteins including granule proteins and mast cell genetic material (DNA and RNA). The HMC-1 line was derived from a patient with mast cell leukemia and we believe it is comprised of immature mast cells. These cells may not respond in all ways as would mature mast cells. HMC-1 cells lack a functional IgE... Read More